Trials / Unknown
UnknownNCT04270344
The Occurrence of MACE in Patients With AMI Receiving Pitavastatin/Valsartan Treatment
A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 905 (estimated)
- Sponsor
- JW Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
Prospective Observation study to identify the rate of MACE in AMI with Livalo V(Pitavastatin/Valsartan) for 12 month in Korea
Detailed description
Following subjects with AMI event within 1 month will be assessed MACE event for 1year * Essential hypertension or heart failure * Idiopathic hypercholesterolemia (heterogeneous familial and non-familial hypercholesterolemia, Fredrickson classification type IIa) * Mixed-type hypercholesterolemia (Fredrickson classification type IIb) with acute myocardial infarction (STEMI, NSTEMI),
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pitavastatin 4mg | combination therapy with pitavastatin/valsartan (LivaloV) |
Timeline
- Start date
- 2018-07-01
- Primary completion
- 2022-06-30
- Completion
- 2022-06-30
- First posted
- 2020-02-17
- Last updated
- 2021-04-13
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04270344. Inclusion in this directory is not an endorsement.